In this file
The published 72-hour cancellation notice deserves attention before renewal. That detail matters when comparing the proposed prescription, payment schedule, and access to help.
This provider file follows the company’s published material and the questions it leaves open. It covers the care arrangement, price, cancellation boundaries, and contact routes; it does not certify the business or determine whether a treatment is appropriate for a particular person.
Understand the care arrangement
VivioMD describes an online assessment and ongoing support with both personalized and branded medication options. Its homepage makes broad access and pricing claims, while the separate refund policy gives more specific rules for subscriptions. Reading that policy is necessary to understand what cancelling anytime actually entails.
Name the organizations involved in your own plan. The website operator, clinical practice, and pharmacy may be separate businesses. A patient should know which one is responsible for a medical decision, which holds the account, and which handles the medication.
Read the price in its proper context
The page lists personalized GLP-1 tablets and injections from $299 per month, GLP-1/GIP injections from $398, and Ozempic from $1,299. These are different products and routes. Ask which preparation and supply duration the personal quote covers instead of comparing only the displayed monthly number.
Record the total paid today, the period it buys, and the next payment. If a figure is expressed per month but collected for several months, keep both numbers in the comparison. Our price-comparison worksheet helps separate a low initial figure from the continuing commitment.
Find the cancellation boundary
VivioMD’s policy requires a cancellation request at least 72 hours before the next billing date to stop that cycle. It allows requests through support@viviomd.com or the patient account where available, and describes a full refund for medical disqualification. A late request may take effect in the following cycle.
A useful request names the next renewal and the current order separately. Ask for confirmation of both the effective cancellation date and the pharmacy status. Instructions for stopping or changing the medicine itself need to come from the treating professional.
Identify the actual prescription
A dissolvable personalized tablet, an injection, and a branded product should not be treated as interchangeable. Ask the clinician to identify the actual product and its regulatory status. A statement that doses share a price is a billing claim, not proof that different formulations have equivalent evidence.
FDA approval concerns a particular drug product. A compounded preparation has not received that approval, and evidence for a different formulation cannot guarantee an individual result. Read the product-approval explanation and ask questions about the exact medicine proposed.
Contact and account help
VivioMD’s published contact number is (678) 258-9290. The documented email route is support@viviomd.com.
The cancellation policy specifies at least 72 hours of notice before renewal; phone is published on the homepage.
Start from the official VivioMD website to find its verified patient-account navigation. We have not signed into a private portal or measured its support response. Do not share passwords, access codes, payment-card details, or medical records with a review site.
Bring one concrete question to the consultation
Which product would I receive, and what is the last date and time to cancel before my next billing cycle?
Write the answer beside the proposed prescription and agreement. If it describes a different product, an expired promotion, or a plan you are not eligible for, ask for clarification. Our pre-purchase checklist can help keep those questions organized.
Source notes
Provider material describes the company’s own offer. Official medical references explain clinical and regulatory context; they do not endorse this publication or its commercial partner.
- refund-policy ↗Provider-published information · Checked September 22, 2026
- viviomd.com ↗Provider-published information · Checked September 22, 2026
- FDA: concerns with unapproved GLP-1 drugs ↗Regulatory / public agency · Checked September 22, 2026
- FDA: risks of compounded drugs ↗Regulatory / public agency · Checked September 22, 2026